NEW YORK (GenomeWeb News) – Qiagen said today that Health Canada has licensed its artus PCR-based hepatitis B virus assay to monitor the viral load of HBV-infected patients.
The company said that the assay kit is in compliance with Health Canada's medical device requirements and is now available to doctors in Canada to help evaluate the efficacy of treatment.
Qiagen said that the kit is configured for Roche’s LightCycler RT-PCR instrument and includes reagents to detect the HBV genotypes A-G. The company said these genotypes are “representative of strains of the virus which can be found globally, ensuring highest sensitivity in monitoring of treatments.”
Financial terms of the agreement were not provided.